Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O4NJ
|
|||
| Former ID |
DIB009282
|
|||
| Drug Name |
Z-100
|
|||
| Synonyms |
Ancer; SSM; Specific Substance of Maruyama; Ancer 20
Click to Show/Hide
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 1 | [1] | |
| Company |
Zeria Pharmaceutical Co Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interferon receptor (IFNR) | Target Info | Modulator | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00016692) Safety and Tolerability of Z-100 in Patients With Early HIV Infection. U.S. National Institutes of Health. | |||
| REF 2 | Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages. J Gen Virol. 2004 Sep;85(Pt 9):2603-13. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.